enVVeno Medical CorpNASDAQ:NVNO
- LAST PRICE4.7500
- TODAY'S CHANGE (%)-0.3600 (-7.0450%)
- Bid / Lots4.7100/ 4
- Ask / Lots4.9300/ 2
- Open / Previous Close5.1000 / 5.1100
- Day Range
- 52 Week Range
- Volume188,607
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NVNO |
|---|---|---|
| 09:32 ET | 2600 | 5.1 |
| 09:34 ET | 3550 | 5.12 |
| 09:39 ET | 5986 | 5.0144 |
| 10:21 ET | 100 | 5.0888 |
| 10:24 ET | 6874 | 5 |
| 10:26 ET | 200 | 5.015 |
| 10:32 ET | 105 | 5 |
| 10:33 ET | 800 | 5 |
| 10:46 ET | 100 | 5 |
| 10:51 ET | 5000 | 4.97 |
| 10:53 ET | 5000 | 4.97 |
| 11:06 ET | 444 | 4.98 |
| 11:08 ET | 140 | 5 |
| 11:22 ET | 2026 | 4.95 |
| 11:29 ET | 200 | 4.9996 |
| 11:40 ET | 401 | 4.97 |
| 11:47 ET | 400 | 4.95 |
| 11:51 ET | 11000 | 4.9254 |
| 11:54 ET | 15822 | 4.9 |
| 12:03 ET | 841 | 4.9 |
| 12:05 ET | 1800 | 4.895 |
| 12:09 ET | 1600 | 4.85 |
| 12:21 ET | 300 | 4.85 |
| 12:34 ET | 5500 | 4.85 |
| 12:36 ET | 900 | 4.85 |
| 12:38 ET | 500 | 4.855 |
| 12:39 ET | 1841 | 4.85 |
| 12:41 ET | 500 | 4.8463 |
| 12:43 ET | 200 | 4.85 |
| 12:45 ET | 1000 | 4.85 |
| 12:50 ET | 4758 | 4.75 |
| 12:52 ET | 2132 | 4.8 |
| 12:54 ET | 602 | 4.83 |
| 12:57 ET | 200 | 4.82 |
| 01:10 ET | 200 | 4.82 |
| 01:12 ET | 350 | 4.8299 |
| 01:14 ET | 1579 | 4.76 |
| 01:19 ET | 834 | 4.82 |
| 01:30 ET | 2640 | 4.75 |
| 01:32 ET | 710 | 4.78 |
| 01:37 ET | 100 | 4.765 |
| 01:46 ET | 1535 | 4.75 |
| 01:48 ET | 2672 | 4.78 |
| 01:51 ET | 125 | 4.78 |
| 01:55 ET | 1000 | 4.7706 |
| 02:00 ET | 11405 | 4.7799 |
| 02:02 ET | 1600 | 4.7164 |
| 02:04 ET | 500 | 4.745 |
| 02:09 ET | 323 | 4.75 |
| 02:11 ET | 3499 | 4.7799 |
| 02:18 ET | 7700 | 4.75 |
| 02:20 ET | 500 | 4.75 |
| 02:22 ET | 102 | 4.755 |
| 02:27 ET | 4350 | 4.69 |
| 02:33 ET | 2995 | 4.7563 |
| 02:38 ET | 1176 | 4.7 |
| 02:40 ET | 250 | 4.68 |
| 02:42 ET | 1700 | 4.7 |
| 02:47 ET | 700 | 4.745 |
| 02:49 ET | 1000 | 4.745 |
| 02:51 ET | 3500 | 4.745 |
| 02:54 ET | 3500 | 4.74 |
| 02:56 ET | 200 | 4.725 |
| 02:58 ET | 1000 | 4.75 |
| 03:02 ET | 207 | 4.77 |
| 03:03 ET | 5662 | 4.75 |
| 03:05 ET | 193 | 4.76 |
| 03:07 ET | 2711 | 4.755 |
| 03:12 ET | 3540 | 4.7201 |
| 03:14 ET | 1822 | 4.75 |
| 03:20 ET | 2041 | 4.76 |
| 03:32 ET | 550 | 4.765 |
| 03:36 ET | 1296 | 4.78 |
| 03:38 ET | 608 | 4.72 |
| 03:41 ET | 100 | 4.782683 |
| 03:43 ET | 1700 | 4.72 |
| 03:48 ET | 250 | 4.755 |
| 03:52 ET | 139 | 4.76 |
| 03:59 ET | 14860 | 4.75 |
Sep 3, 2024
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing, from 9:03AM ET on Tuesday Sep 03, 2024 by Dow Jones
9:03AM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
enVVeno Medical Corp | 63.3M | -3.3x | --- |
RetinalGenix Technologies Inc | 62.5M | -15.3x | --- |
RAPT Therapeutics Inc | 62.5M | -0.6x | --- |
Vor Biopharma Inc | 61.6M | -0.5x | --- |
CEL-SCI Corp | 66.4M | -1.9x | --- |
Connect Biopharma Holdings Ltd | 68.0M | -3.2x | --- |
Company Information
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
Contact Information
- Headquarters
- 70 DopplerIRVINE, CA, United States 92618-4306
- Phone
- 949-261-2900
- Fax
- 949-261-2992
Executives
- Chief Executive Officer, Director
- Robert Berman
- Chief Financial Officer, Treasurer
- Craig Glynn
- Senior Vice President, Chief Technology Officer
- Hamed Alavi
- Senior Vice President, Chief Medical Officer
- Marc Glickman
- Chief Commercial Officer
- Andrew Cormack
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $63.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-1.43 |
Book Value | $3.47 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
